Margaret Anderson, Managing Director
Deloitte
Charlene Banard, Head of Quality, Technical Operations
Shire
Jeffrey Berkowitz, Former EVP
UnitedHealth Group
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEO
Amicus Therapeutics
Rich Daly, Chairman & CEO
Neuralstem
Raúl Díaz, Plant Manager, MSD Pharmaceutical Operations
Merck, Mexico
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Tim Garnett, M.D., CMO & SVP of Medicines Development
Eli Lilly
Anu Hans, VP & CPO Enterprise Supply Chain
J&J
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
John Hubbard, Ph.D., Board Member
Agile Therapeutics
Maik Jornitz, CEO
G-CON Manufacturing
Mitchell Katz, Ph.D., Head of Medical Research & Drug Safety Operations
Purdue Pharma
Mary Rose Keller, VP, Clinical Operations
Heron Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Ventures
Craig Lipset, Head of Clinical Innovation, Global Product Development
Pfizer
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, President & CEO
Cognition Therapeutics
Bernard Munos, Founder
InnoThink Center for Research in Biomedical Innovation
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Sesha Neervannan, Ph.D., SVP Pharmaceutical Development
Allergan
Julia Owens, Ph.D., President and CEO
Millendo Therapeutics
Mark Petrich, Ph.D., PE, Director, Single-Use Systems Engineering
Merck
Sandra Poole, Chief Operating Officer
LogicBio Therapeutics Inc.
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
John Reynders, Ph.D., VP, Data Sciences, Genomics, & Bioinformatics
Alexion Pharmaceuticals
James Robinson
Independent Manufacturing Consultant
Tomasz Sablinski,M.D., Ph.D., Cofounder & CEO
Transparency Life Sciences
Chhaya Shah, SVP Technical Operations
Synergy Pharmaceuticals
Andrew Skibo, EVP Operations
MedImmune RVP, AstraZeneca
Jason Urban, Ph.D., Sr. Director, Business Operational Excellence
Celgene
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Leslie Williams, Founder, President & CEO
ImmusanT

IN THIS MONTH'S ISSUE

  • What Will The Next 10 Years Bring For Biopharma?

    The biopharma industry has changed significantly during the past 10 years, and so has Life Science Leader. What will the next decade have in store for issues such as drug pricing and new therapeutic advances?

  • Why A Spin-off Is A Win-Win For Big Pharma And Startups

    When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.

  • Speedy & Profound Culture Change Through Self-Enrollment

    When Baxter spun off its biotechnology operations into an independent entity named Baxalta, its management team began executing a successful culture change with a unique self-enrollment model. This is the story of how that self-enrollment model worked.

  • Medicare Advantage: The Solution To Value-Based Care

    As Congress grapples with complex ways to provide greater care coordination for seniors with multiple chronic conditions and value-based reimbursement schemes for prescription drugs, an obvious solution is being fundamentally ignored: greater enrollment in Medicare Advantage (MA).

  • Building New Business Models To Support Cell And Gene Therapy R&D

    Gene and cell therapy research has progressed despite the considerable challenges that require new approaches to the standard drug-development process and timeline. Here are some alternate development and financing models to consider.

More From Current Issue

@LIFESCILEADER1

 EVENTS

Cleanroom Microbiology – A Foundational Introduction July 24 - 24, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Using Social Media for Patient Recruitment in Clinical Trials July 26 - 26, 2018
1)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Writing Effective 483 and Warning Letter Responses August 2 - 2, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
The Medical Device Reporting (MDR) Guidance – An Easily Digestible Compliance Breakdown August 7 - 7, 2018
1pm-2:30pm EST, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Communicating Beyond the Label: FDA’s Finalized Guidances & Updates August 8 - 8, 2018
1pm-2:30pm EDT, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!